Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,929 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01190176 | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects | completed | Phase 3 | 34 | GlaxoSmithKlineINDUSTRY | 7 | Oct 30, 2019 | clinicaltrials |
| NCT00937950 | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects | completed | Phase 3 | 2,022 | GlaxoSmithKlineINDUSTRY | 13 | Oct 29, 2019 | clinicaltrials |
| NCT03610100 |
| Acelarin First Line Randomised Pancreatic Study(ACELARATE) |
| suspended |
| Phase 2 / Phase 3 |
| 328 |
| The Clatterbridge Cancer Centre NHS Foundation TrustOTHER |
| 1 |
| Oct 29, 2019 |
| clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT02578940 | Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer(FALCON) | completed | Phase 3 | 104 | Blue Earth DiagnosticsINDUSTRY | 1 | Oct 7, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01168973 | A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | completed | Phase 3 | 1,253 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 25, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT01721044 | A Moderate to Severe Rheumatoid Arthritis Study(RA-BEACON) | completed | Phase 3 | 527 | Eli Lilly and CompanyINDUSTRY | 22 | Sep 18, 2019 | clinicaltrials |
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | completed | Phase 3 | 400 | AGC Biologics S.p.A.INDUSTRY | 12 | Sep 17, 2019 | clinicaltrials |
| NCT01091168 | Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer | completed | Phase 3 | 594 | Pierre Fabre MedicamentINDUSTRY | 14 | Sep 16, 2019 | clinicaltrials |
| NCT00087711 | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 3 | 1,713 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 12, 2019 | clinicaltrials |
| NCT00295815 | Enzastaurin Versus Lomustine in Glioblastoma | completed | Phase 3 | 397 | Eli Lilly and CompanyINDUSTRY | 14 | Sep 12, 2019 | clinicaltrials |
| NCT02555878 | A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants | completed | Phase 3 | 841 | Janssen Research & Development, LLCINDUSTRY | 10 | Sep 12, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment(IMPALA) | unknown | Phase 3 | 540 | Mologen AGINDUSTRY | 8 | Sep 10, 2019 | clinicaltrials |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients(EGF) | terminated | Phase 3 | 106 | Bioven EuropeINDUSTRY | 11 | Sep 10, 2019 | clinicaltrials |
| NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy(ADI-PEG 20) | completed | Phase 3 | 636 | Polaris GroupINDUSTRY | 6 | Sep 6, 2019 | clinicaltrials |
| NCT02402712 | Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | completed | Phase 3 | 418 | Hoffmann-La RocheINDUSTRY | 12 | Sep 6, 2019 | clinicaltrials |
| NCT01322490 | A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer(Prospect) | completed | Phase 3 | 1,297 | Bavarian NordicINDUSTRY | 16 | Sep 4, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT00137995 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | completed | Phase 3 | 481 | Lymphoma Study AssociationOTHER | 10 | Aug 28, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | terminated | Phase 3 | 161 | Gilead SciencesINDUSTRY | 5 | Aug 20, 2019 | clinicaltrials |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 261 | Gilead SciencesINDUSTRY | 11 | Aug 14, 2019 | clinicaltrials |
| NCT01901146 | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer(Lilac) | completed | Phase 3 | 725 | AmgenINDUSTRY | 18 | Aug 7, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | completed | Phase 3 | 831 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 31, 2019 | clinicaltrials |
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | completed | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 21 | Jul 16, 2019 | clinicaltrials |
| NCT03008551 | Empagliflozin vs Metformin in PCOS | completed | Phase 2 / Phase 3 | 40 | Hull University Teaching Hospitals NHS TrustOTHER_GOV | 1 | Jul 15, 2019 | clinicaltrials |
| NCT01310894 | Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.(PCM301) | completed | Phase 3 | 413 | Steba Biotech S.A.OTHER | 10 | Jul 11, 2019 | clinicaltrials |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | terminated | Phase 3 | 143 | Alexion Pharmaceuticals, Inc.INDUSTRY | 18 | Jun 26, 2019 | clinicaltrials |
| NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia(COMPLEMENT 1) | terminated | Phase 3 | 447 | Novartis PharmaceuticalsINDUSTRY | 17 | Jun 25, 2019 | clinicaltrials |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | completed | Phase 3 | 454 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 6 | Jun 6, 2019 | clinicaltrials |
| NCT01915693 | ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study(ROCS) | completed | Phase 3 | 220 | Lisette NixonOTHER_GOV | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT00647530 | Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery(FOxTROT) | unknown | Phase 2 / Phase 3 | 1,053 | University of BirminghamOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 220 | Gilead SciencesINDUSTRY | 5 | May 14, 2019 | clinicaltrials |
| NCT01259856 | Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | completed | Phase 3 | 168 | Ronald HoffmanOTHER | 4 | Apr 30, 2019 | clinicaltrials |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | terminated | Phase 3 | 1,418 | Hoffmann-La RocheINDUSTRY | 29 | Apr 12, 2019 | clinicaltrials |
| NCT00820222 | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | completed | Phase 3 | 540 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 2, 2019 | clinicaltrials |
| NCT01846611 | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 581 | Janssen Research & Development, LLCINDUSTRY | 10 | Apr 1, 2019 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials